Histogenics Corporation (HSGX) Analysts See $-0.22 EPS

February 20, 2018 - By Nellie Frank

 Histogenics Corporation (HSGX) Analysts See $ 0.22 EPS

Analysts expect Histogenics Corporation (NASDAQ:HSGX) to report $-0.22 EPS on March, 15.They anticipate $1.38 EPS change or 86.25 % from last quarter’s $-1.6 EPS. After having $-0.23 EPS previously, Histogenics Corporation’s analysts see -4.35 % EPS growth. The stock increased 0.77% or $0.02 during the last trading session, reaching $2.63. About 20,295 shares traded. Histogenics Corporation (NASDAQ:HSGX) has declined 7.61% since February 20, 2017 and is downtrending. It has underperformed by 24.31% the S&P500.

Histogenics Corporation (NASDAQ:HSGX) Ratings Coverage

Among 6 analysts covering Histogenics Corp (NASDAQ:HSGX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Histogenics Corp had 16 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Friday, November 13. The stock has “Buy” rating by BTIG Research on Friday, August 12. The rating was maintained by Canaccord Genuity on Monday, October 16 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $3.5 target in Thursday, November 2 report. The firm has “Hold” rating by Zacks given on Thursday, August 27. The firm earned “Buy” rating on Thursday, December 21 by Canaccord Genuity. Needham maintained Histogenics Corporation (NASDAQ:HSGX) rating on Friday, November 13. Needham has “Buy” rating and $15 target. H.C. Wainwright maintained it with “Buy” rating and $3.5 target in Wednesday, December 27 report. BTIG Research downgraded the shares of HSGX in report on Friday, November 13 to “Neutral” rating. H.C. Wainwright initiated Histogenics Corporation (NASDAQ:HSGX) on Monday, December 19 with “Buy” rating.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company has market cap of $64.62 million. The firm offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It currently has negative earnings. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

More important recent Histogenics Corporation (NASDAQ:HSGX) news were published by: Globenewswire.com which released: “Histogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as …” on June 05, 2017, also Globenewswire.com published article titled: “Histogenics Corporation Announces Second Quarter 2017 Financial and Operating …”, Gurufocus.com published: “S Squared Technology, LLC Buys Rapid7 Inc, Histogenics Corp, Adtran Inc, Sells …” on February 13, 2018. More interesting news about Histogenics Corporation (NASDAQ:HSGX) was released by: Globenewswire.com and their article: “Histogenics Announces Agreement With the Japan Pharmaceuticals and Medical …” with publication date: May 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.